No. 108, Meiliang Road
Mashan
Wuxi 214092
China
https://www.wuxibiologics.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 12,740
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Dr. Ge Li Ph.D. | Founder & Chairman | N/A | N/A | 1967 |
Dr. Zhisheng Chen | CEO & Executive Director | 4.87M | N/A | 1973 |
Dr. Weichang Zhou Ph.D. | Honorary President of Global Biologics Development, Senior Advisor to CEO & Non-Executive Director | 3.27M | N/A | 1964 |
Mr. Ming Tu | CFO & Executive VP | N/A | N/A | 1968 |
Ms. Tang Shaogui M.B.A. | VP and Head of Global Communications, Operations & ESG | N/A | N/A | N/A |
Dr. Sherry Gu | Chief Technology Officer and Executive VP of Global Biologics Development Department | N/A | N/A | 1971 |
Dr. Jijie Gu | Executive VP & Chief Scientific Officer | N/A | N/A | 1966 |
Ms. Eileen Wang | IR Senior Director | N/A | N/A | N/A |
Ms. Cong Ding J.D. | VP & Head of Legal Department | N/A | N/A | N/A |
He Wang | Chief Compliance Officer, Senior VP and Head of Global Compliance & Risk Management | N/A | N/A | N/A |
WuXi Biologics (Cayman) Inc. provides end-to-end solutions and services for biologics discovery, development, and manufacturing in the People's Republic of China, North America, Europe, and internationally. It also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, and biologics clinical and manufacturing services; production and sale of medicals; vaccine contract development and manufacturing organization (CDMO) and related business; and material supplier activities. The company has a research service agreement with BioNTech SE to discover and investigate monoclonal antibodies for developing next-generation therapeutic product candidates. The company was incorporated in 2014 and is headquartered in Wuxi, China.
WuXi Biologics (Cayman) Inc.’s ISS Governance QualityScore as of April 1, 2024 is 9. The pillar scores are Audit: 2; Board: 10; Shareholder Rights: 4; Compensation: 9.